Millennium Pharmaceuticals, Inc. has signed an agreement for an expanded alliance with MorphoSys AG. Under their agreement, MorphoSys AG will apply its proprietary HuCAL technology to generate human antibodies for a new target molecule in inflammatory disorders provided by Millennium. One of the objectives of the alliance is to develop fully human antibodies against targets Read more about Millennium And Morphosys Extend Collaboration[…]